{"entity":{"id":"cdr-life","kind":"company","name":"CDR-Life","aka":[],"tldr":"CDR-Life develops T cell engagers, antibody-based medicines that bring the immune system's T cells into contact with cancer cells. Its cancer medicine CDR404 targets the MAGE-A4 protein and is in an early trial in solid tumours, now focusing on ovarian cancer.","summary":"CDR-Life AG, in Horgen near Zurich, Switzerland, was founded in 2017, according to the company. Its M-gager platform makes antibody-based T cell engagers for cancer and autoimmune disease. CDR404 is a bivalent, bispecific T cell engager against MAGE-A4 in HLA-A*02:01 patients; the FDA cleared its IND in January 2024, enrolment in the phase 1 trial (NCT06402201) began in May 2024 and the first patient was dosed by September 2024. In October 2025 the company reported pharmacodynamic activity in MAGE-A4-positive solid tumours and said the trial would focus on MAGE-A4-positive ovarian cancers. Other programmes include CDR609 against LGR5, and a Boehringer Ingelheim partnership in geographic atrophy and autoimmune disease, including a November 2025 global licence for CDR111 with up to CHF 456 million in payments. Its first registered cancer trial, NCT06402201, was posted on ClinicalTrials.gov in May 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.cdr-life.com/"},{"label":"ClinicalTrials.gov: phase 1 trial of CDR404 (NCT06402201)","url":"https://clinicaltrials.gov/study/NCT06402201"},{"label":"CDR-Life: early clinical data for CDR404 (October 2025)","url":"https://www.cdr-life.com/wp-content/uploads/2025/10/pr-10-23-2025_CDR-Life-Presents-Early-Clinical-Data-Demonstrating-Pharmacodynamic-Activity-of-CDR404.pdf"}],"tags":[],"related":[],"cancers":["ovarian"],"sections":["immunotherapy"],"technologies":["t-cell-engager","bispecific-antibody"],"targets":["mage-a4"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No financing rounds or investors are named on the company website; it says only that it is backed by cross-Atlantic investors.","The Boehringer Ingelheim figures (up to CHF 456 million, about 570 million US dollars, and CHF 38 million) are partnership payments, not equity financing, and are kept out of funding.","Company website and news list read on 29 October 2026."],"hq":"Horgen","country":"CH","companyType":"biotech","website":"https://www.cdr-life.com/","founded":2017,"investors":[],"funding":[]},"route":"/companies/cdr-life/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"mage-a4","kind":"target","name":"MAGE-A4","route":"/targets/mage-a4/"}]}}